Connect® MM- The Multiple Myeloma Disease Registry

Study Overview
=================
Brief Summary
-----------------
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Official Title
-----------------
Connect® MM- The Multiple Myeloma Disease Registry

Conditions
-----------------
Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect®MM registry Age ≥18 years Willing and able to provide signed informed consent Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel Exclusion Criteria: - None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group One: Patients enrolled between Sep2009 and Nov2011<br>Newly diagnosed multiple myeloma patients enrolled between Sep 2009 and Nov 2011. | |
| Group Two: Patients enrolled between Dec2012 and mid-2016<br>Newly diagnosed multiple myeloma patients enrolled between Dec 2012 and mid-2016 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identify and summarize patterns in therapeutic regimens | Describe practice patterns of common first-line treatment regimens and subsequent therapeutic strategies in patients newly diagnosed with symptomatic MM in the community and academic setting | Minimum 8 years | 
| Identify and summarize patterns in therapeutic regimens and patient outcomes | Provide insight into treatment regimens and therapy sequence in clinical practice as they relate to clinical outcomes (response, overall survival, progression-free survival) in patients newly diagnosed with symptomatic MM | Minimum 8 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Summarize Effectiveness of Treatment Regimens | Describe any differences in effectiveness associated with different treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects (such as proximity of academic centers) in patients newly diagnosed with symptomatic MM | Minimum 8 years | 
| Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes | Describe the health-related quality of life (HRQoL) of patients newly diagnosed with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes | Minimum 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Myeloma, MM, disease registry, Connect®